Ovarian cancer is caused by a harmful overgrowth of cells in and around the ovaries. The cancer can start in the lining of the ovary or fallopian tube, the supportive tissue, or in the egg cell. There ...

Pembrolizumab is under clinical development by Merck and currently in Phase II for Dysgerminoma. According to GlobalData, Phase II drugs for Dysgerminoma does not have sufficient historical data to ...